From the Department of Emergency Medicine, Wake Forest University School of Medicine, Winston-Salem, NC.
Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC.
Crit Pathw Cardiol. 2023 Dec 1;22(4):110-113. doi: 10.1097/HPC.0000000000000338. Epub 2023 Oct 13.
Hypercholesterolemia (HCL) affects nearly half of Emergency Department (ED) patients who present with possible acute coronary syndrome (ACS). However, it is unknown whether US ED providers obtain lipid panels, calculate 10-year atherosclerotic cardiovascular disease (ASCVD) risk, and prescribe cholesterol-lowering medications for these patients.
We conducted a nationwide cross-sectional ED survey from April 18, 2023, to May 12, 2023. An electronic survey assessing current preventive HCL care practices for patients being evaluated for ACS. A convenience sample was obtained by sharing the survey with ED medical directors, chairs, and senior leaders using emergency medicine professional organization listservs and snowball sampling. Responding EDs were categorized as being associated with an academic medical center (AMC) or not (non-AMC).
During the 4-week study period, 110 EDs (50 AMC and 60 non-AMC EDs) across 39 states responded. Just 1.8% (2/110) stated that their providers obtain a lipid panel on at least half of patients with possible ACS and only one ED (0.9%) responded that its providers calculate 10-year ASCVD risk and prescribe cholesterol medication for the majority of eligible patients. Most reported never obtaining lipid panels (60.9%, 67/110), calculating 10-year ASCVD risk (55.5%, 61/110), or prescribing cholesterol-lowering medications (52.7%, 58/110).
The vast majority of US ED providers do not provide preventive cardiovascular care for patients presenting with possible ACS. Most ED providers do not evaluate for HCL, calculate ASCVD risk, or prescribe cholesterol-lowering medications for these patients.
高胆固醇血症(HCL)影响近半数因可能的急性冠脉综合征(ACS)而就诊的急诊科(ED)患者。然而,目前尚不清楚美国 ED 医护人员是否为这些患者检测血脂谱、计算 10 年动脉粥样硬化性心血管疾病(ASCVD)风险并开具降胆固醇药物。
我们于 2023 年 4 月 18 日至 5 月 12 日进行了一项全国性的 ED 横断面调查。采用电子问卷调查评估 ACS 评估患者的当前预防性 HCL 护理实践。通过向 ED 主任、主席和高级领导分享调查,利用急诊医学专业组织列表和滚雪球抽样,获得便利样本。参与调查的 ED 分为与学术医疗中心(AMC)相关和不相关(非 AMC)。
在 4 周的研究期间,来自 39 个州的 110 家 ED(50 家 AMC 和 60 家非 AMC ED)做出了回应。仅有 1.8%(2/110)表示其医护人员至少对一半可能患有 ACS 的患者进行血脂谱检测,只有 1 家 ED(0.9%)表示其医护人员为大多数符合条件的患者计算 10 年 ASCVD 风险并开具降胆固醇药物。大多数报告称从未进行过血脂谱检测(60.9%,67/110)、计算 10 年 ASCVD 风险(55.5%,61/110)或开具降胆固醇药物(52.7%,58/110)。
绝大多数美国 ED 医护人员并未为因可能的 ACS 就诊的患者提供预防性心血管护理。大多数 ED 医护人员不会为这些患者检查 HCL、计算 ASCVD 风险或开具降胆固醇药物。